Pharmaceutical Technology

JANUARY 27, 2023

The UK National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending the use of Kite’s axicabtagene ciloleucel (yescarta) to treat aggressive forms of lymphoma. This news illustrates how NICE is determined to get the best care to patients fast, while ensuring value for money for the taxpayer.”

Gene Therapy 147

Gene Therapy Clinical Trials Clinical Trials Gene 147

Drug Discovery World

DECEMBER 15, 2023

News round-up for 11-15 December by DDW Digital Content Editor Diana Spencer. in large B-cell lymphoma (LBCL) patients treated with axicabtagene ciloleucel (Yescarta). in large B-cell lymphoma (LBCL) patients treated with axicabtagene ciloleucel (Yescarta). and complete response rate (CR) of 57.7%

Drugs 52

Drugs Clinical Trials Clinical Trials Manufacturing 52

Pharmaceutical Technology

OCTOBER 3, 2022

Cancer Research UK Policy Development head Kruti Shrotri said: “This decision is good news for people affected by Waldenstrom’s macroglobulinaemia. WM is a rare non-Hodgkin lymphoma type that develops in white blood cells.

Clinical Trials 262

Clinical Trials Clinical Trials Trials Development 262

pharmaphorum

MAY 27, 2022

Roche will present the new data at next week’s ASCO congress showing that its bispecific antibody glofitamab can achieve high and durable responses in patients with aggressive lymphoma. The post Roche trumpets new glofitamab data in lymphoma at ASCO appeared first on.

Antibody 67

Antibody Sales Trials Development 67

STAT News

DECEMBER 12, 2022

NEW ORLEANS – An experimental immunotherapy from Affimed for patients with advanced Hodgkin lymphoma has started to demonstrate long-lasting remissions that have, so far, eluded other treatments involving so-called natural killer cells.

Manufacturing 98

Manufacturing Drugs 98

STAT News

DECEMBER 23, 2022

Your loyal scribe Ed Silverman is taking today off, so he bestowed upon me, Adam Feuerstein, the great honor of delivering today’s roundup of pharma news. The new drug, called Lunsumio, is a so-called bispecific antibody, which works by attaching to cancer cells with one arm of the drug, and T cells with a second arm.

FDA Approval 98

FDA Approval Immune Response Drugs Research 98

Drug Discovery World

NOVEMBER 3, 2023

News round-up for 30 October – 3 November by DDW Editor Reece Armstrong My news highlights this week feature a variety of exciting clinical trial results and launches that are examining therapies for much-needed disease areas, new drug approvals and even a space mission with a pharma twist.

Drugs 52

Drugs Gene Therapy Clinical Trials Clinical Trials 52

Drug Discovery World

DECEMBER 19, 2023

Our news highlights this week focus on haematology, thanks in part to a number of key announcements at the 65th American Society for Hematology meeting (ASH) Annual Meeting, including real-world evidence on the use of CAR-T therapies in blood cancers and new data for myeloma and lymphoma treatments.

Drugs 59

Drugs Research 59

Drug Discovery World

DECEMBER 19, 2023

Our news highlights this week focus on haematology, thanks in part to a number of key announcements at the 65th American Society for Hematology meeting (ASH) Annual Meeting, including real-world evidence on the use of CAR-T therapies in blood cancers and new data for myeloma and lymphoma treatments.

Drugs 52

Drugs 52

Pharmaceutical Technology

MARCH 3, 2023

This announcement is welcome news for patients with non-transfusion-dependent beta thalassemia-associated anaemia across the EU seeking newer treatment options to reduce these burdens. The study was designed to assess the safety and efficacy of Reblozyl against placebo in 145 NTD beta thalassemia adult patients.

Marketing 147

Marketing Clinical Development Development 147

Drug Discovery World

JULY 31, 2023

To coincide with the publication of the DDW eBook ‘ Antibody discovery: Breakthroughs accelerating therapeutic antibodies ’, our news highlights this week all focus on antibodies, particularly the recommendation by the EU’s CHMP for two bispecific antibodies that treat multiple myeloma and lymphoma.

Antibody 52

Antibody Drugs 52

Camargo

FEBRUARY 4, 2021

Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. In the News: March 2021 Regulatory and Development Updates. In the News: February 2021 Regulatory and Development Updates.

Development 131

Development Production Drugs Manufacturing 131

Drug Discovery World

JULY 31, 2023

To coincide with the publication of the DDW eBook ‘ Antibody discovery: Breakthroughs accelerating therapeutic antibodies ’, our news highlights this week all focus on antibodies, particularly the recommendation by the EU’s CHMP for two bispecific antibodies that treat multiple myeloma and lymphoma.

Antibody 52

Antibody Drugs Research 52

Drug Discovery World

MARCH 22, 2024

News round-up for 18-22 March by DDW Digital Content Editor Diana Spencer. This has been an interesting week for cell and gene therapies, with two landmark FDA approvals, two significant fundraising efforts and potentially ground-breaking study results in glioblastoma.

Gene Therapy 52

Gene Therapy In-Vivo FDA Approval Drugs 52

pharmaphorum

OCTOBER 8, 2021

A phase 1 trial of Allogene’s of-the-shelf CAR-T for lymphoma has been placed on hold by the FDA, after a “chromosomal abnormality” was seen in a patient receiving the cell therapy. Off the shelf or allogeneic cell therapies are derived from a bank of cells and can be manufactured and administered in bulk like drugs.

Trials 52

Trials Gene Editing Genetics Gene 52

World of DTC Marketing

FEBRUARY 2, 2022

Biogen will partner with Roche on the development, and potential sale of a promising cancer drug the Swiss pharma is advancing for several types of lymphoma, announcing Tuesday it’s exercised an option to share rights to the treatment. But is it too late for Biogen to stage a comeback with their reputation damaged?

FDA Approval 239

FDA Approval Drugs Doctors Doctor 239

The Pharma Data

NOVEMBER 20, 2020

Rates of VTE, Major Bleeding High in Primary CNS Lymphoma. 20, 2020 — For patients with primary central nervous system lymphoma (PCNSL), the incidence of venous thromboembolism (VTE) and major bleeding is high, according to a study published in the November issue of Leukemia & Lymphoma. More News Resources.

Medicine 52

Medicine Development Research 52

Drug Discovery World

JULY 28, 2023

News round-up for 24-28 July by DDW Digital Content Editor Diana Spencer. The top stories: Partnership could enhance antibody discovery for cancer research Cancer Research Horizons has signed a collaboration agreement to license the entire Twist Biopharma Solutions Library of Libraries.

Antibody 52

Antibody Drugs Medicine Clinical Trials 52

Drug Discovery World

OCTOBER 27, 2023

News round-up for 23-27 October by DDW Digital Content Editor Diana Spencer. My news highlights this week feature a variety of treatment approaches, from cell therapy and antibody-drug conjugate to autotaxin inhibitor and arenaviral vaccine, all entering early in-human clinical trials to treat a range of diseases.

Drugs 52

Drugs Antibody Vaccination Vaccine 52

Drug Discovery World

FEBRUARY 3, 2023

News round-up for 30 January – 3 February by DDW Digital Content Editor Diana Spencer. Commission tackles global access to precision cancer treatments A team of experts from the University of Glasgow will lead a new international effort to improve cancer control and reduce global health inequalities.

Drugs 52

Drugs FDA Approval Development Manufacturing 52

World of DTC Marketing

JANUARY 4, 2022

(Stat News) Today, a study followed 380 patients being treated at community oncology groups across the U.S. While 98% of them had insurance, 71% fell deeper into debt, took out a new loan, sold or refinanced a home, or experienced at least a 20% decline in income — or a combination of these over the year they answered quarterly surveys.

Pharma Companies 273

Pharma Companies Drugs Medicine Research 273

World of DTC Marketing

FEBRUARY 17, 2022

The team also found that medication was the most significant expense and that medication expenses for breast, lung, lymphoma and colorectal cancers incurred the most costs. It’s both good and bad news. According to a team of Penn State College of Medicine researchers, care for the 15 most prevalent types of cancer in the U.S.

Medicine 271

Medicine Drugs Research Marketing 271

Drug Discovery World

JULY 24, 2023

It has been recommended for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and paediatric patients (one month and older) who developed hypersensitivity or silent inactivation to E. coli-derived asparaginase.

Drugs 52

Drugs Medicine Development Production 52

BioTech 365

AUGUST 18, 2020

DGAP-News: MorphoSys AG / Key word(s): Miscellaneous 18.08.2020 / 22:02 The issuer is solely responsible for the content of this announcement.

40

40

Bioengineer

JULY 23, 2021

MUSC Hollings Cancer Center part of promising clinical trial for aggressive lymphoma. MUSC Hollings Cancer Center was one of 28 clinical sites around the world that participated in the LOTIS-2 trial to test the efficacy of Loncastuximab tesirine, a promising new treatment for aggressive B-cell lymphoma. Credit: MUSC Hollings.

Trials 52

Trials Antibody Drugs Clinical Trials 52

BioTech 365

SEPTEMBER 17, 2020

DGAP-News: MorphoSys AG / Key word(s): Miscellaneous 17.09.2020 / 22:05 The issuer is solely responsible for the content of this announcement. MorphoSys and Incyte to Host Investor Event to Discuss the Unmet Need and Global Opportunities for Tafasitamab … Continue reading →

40

40

The Pharma Data

AUGUST 21, 2020

NICE has moved to recommend Roche’s Polivy (polatuzumab vedotin), when combined with rituximab and bendamustine, for the treatment of diffuse large B-cell lymphoma (DLBCL) in adult patients whose disease has relapsed or have not responded to primary treatment and are not eligible for a haematopoietic stem cell transplant.

52

52

The Pharma Data

JANUARY 22, 2021

8 in Leukemia & Lymphoma. More News Resources. Professional. Renal Insufficiency May Worsen Multiple Myeloma Outcomes. FRIDAY, Jan. Ghulam Rehman Mohyuddin, M.D., ” Several authors disclosed financial ties to the pharmaceutical industry. Abstract/Full Text (subscription or payment may be required). © 2021 HealthDay.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Research 52

The Pharma Data

NOVEMBER 12, 2020

Calquence is being developed for the treatment of multiple B-cell blood cancers including chronic lymphocytic leukaemia, mantle cell lymphoma, diffuse large B-cell lymphoma, Waldenström’s macroglobulinaemia, follicular lymphoma, and other haematologic malignancies. More News Resources. AstraZeneca. J Hematol Oncol.

Trials 52

Trials Clinical Trials Clinical Trials Immune Response 52

pharmaphorum

JANUARY 28, 2021

“Patients who receive lenalidomide maintenance after high-dose therapy and stem cell transplant have a significant increase in overall survival, so the decision to make this available through the NHS is fantastic news,” she added. It can also be used as a second- or third-line option in combination with other drugs for relapsed myeloma.

Drugs 98

Drugs Medicine Trials Production 98

pharmaphorum

FEBRUARY 10, 2021

Shares in the biotech almost doubled after the news broke, but fell back as investors digested the data to close up around 50%. Patients who hadn’t previously been treated with a checkpoint inhibitor has a median overall survival (OS) of 24.6

Engineer 97

Engineer Protein Trials Drugs 97

pharmaphorum

JANUARY 3, 2023

The result is good news for Pfizer, which has exclusive marketing rights to the drug in mainland China under an agreement signed in 2020. If approved by China’s National Medical Products Administration (NMPA), it will add to sugemalimab’s existing indications in first- and second-line non-small cell lung cancer (NSCLC).

Trials 57

Trials Sales Marketing Drugs 57

pharmaphorum

MAY 11, 2021

“This is great news for the aHUS community in Scotland, as ravulizumab will reduce the number of infusions needed per year, significantly improving the quality of life for all those living with the condition,” according to David Kavanagh, professor of complement therapeutics at the NRCTC.

Medicine 52

Medicine Sales Drugs Trials 52

The Pharma Data

JANUARY 27, 2021

RIIB antibody BI-1206 in combination with rituximab (anti-CD20 monoclonal antibody) in patients with indolent relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL). (Nasdaq: CASI), a U.S. CEO of BioInvent. ” BioInvent will hold a key opinion leader (KOL) call today, Thursday, January 28 at 5:30 p.m.

Antibody 52

Antibody Containment Development Trials 52

pharmaphorum

DECEMBER 24, 2020

The news comes as former Celgene shareholders wait to see whether the FDA will approve a cancer cell therapy ahead of a deadline on New Year’s Eve. The cancer cell therapy for lymphoma known as liso-cel must be approved by the FDA New Year’s Eve, followed by another CAR-T ide-cel on March 31 next year.

Trials 52

Trials Doctors Doctor Drugs 52

pharmaphorum

JANUARY 19, 2021

Our commitment is to ensure that people in Scotland with lung cancer live longer and healthier lives, and today’s news shows how we are advancing science to achieve this,” she added. NICE is also conducting an appraisal of Tavlesse, but hasn’t yet set a timeframe for review.

Medicine 85

Medicine Gene Drugs Production 85

Triage Cancer

DECEMBER 8, 2020

by Michelle Andrews, Kaiser Health News. A month later Bloechl was diagnosed with stage 4 non-Hodgkin’s lymphoma after an MRI showed tumors on his spine. Our patients are often young and healthy,” said Ryan Holeywell, senior director of advocacy communications at the Leukemia & Lymphoma Society. That was December 2016.

Sales 98

Sales Insulin Doctors Doctor 98